TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial) - Concepedia

Concepedia

Publication | Open Access

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)

DOI Full Paper Access

125

Citations

14

References

2020

Year

Nadine Tung, Banu Arun, Michele R. Hacker, Erin Hofstatter, Deborah Toppmeyer, Steven J. Isakoff, Virginia F. Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff,

Journal of Clinical Oncology

Abstract

pCR or RCB 0/1 is not significantly higher with CDDP than with AC in <i>BRCA</i> carriers with stage I-III HER2-negative breast cancer for both TNBC and ER+/HER2-negative disease.

References

	Year	Citations

Page 1